Cerulean Pharma promotes Scott Eliasof to senior vice president
Before joining Cerulean in 2007, Dr. Eliasof was the director of the Chemical Biology Platform at the Broad Institute, directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science, and software engineering.
Prior to joining the Broad Institute, Dr. Eliasof worked at Millennium Pharmaceuticals, where he managed scientific teams in cellular biology, molecular biology, neuroscience, and bioinformatics for a large-scale genomics-based drug discovery program.
Earlier in his career, Dr. Eliasof was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders.
Dr. Eliasof earned his B.S. from MIT in electrical engineering, Ph.D. from the University of California at Berkeley in neuroscience, and completed his post-doctoral fellowship at the Vollum Institute in Portland, Oregon. ■
LATEST MOVES FROM Massachusetts
- Voyager Therapeutics appoints Matthew P. Ottmer as COO
- Ocular Therapeutix appoints Michael Goldstein as CMO
- Battery Ventures promotes three to vice presidents
- MKS Instruments appoints Mark Gitin as vice president
- Raytheon appoints Christopher J. Davis as international president
More inside POST
Foot Locker Q2 income falls 36% Earnings